Medical Malpractice Insurance News

Experts say patient-centric opioid intervention before discharge from the hospital can cut overall opioid intake, while still ensuring a patient is satisfied and their pain is properly managed.

The U.S. Food and Drug Administration issued an emergency use authorization for simultaneous administration of monoclonal antibodies bamlanivimab and etesevimab to treat COVID-19 patients who meet specific criteria.

ISMP says common medication mishaps can be prevented with proper attention and prioritization that results in system and practice changes.

The Emergency Care Research Institute’s 2021 list of technology hazards can help healthcare facilities effectively manage risks involving the use of medical devices and systems.

Medication stewardship programs are important efforts by all frontline healthcare workers and are becoming more common in dental practices, as well. In dental practices, dentists should exercise particular caution when prescribing antibiotics and opioids.

The Joint Commission’s seven patient safety goals it says should be the prioritized by hospitals in the coming year.

Patient nonadherence to a prescribed medication regimen is a common problem that physicians in all specialties encounter. Review this Risk Management Tip from MLMIC to reinforce related policies and protocols within your practice or facility.

The U.S. Food and Drug Administration has granted Eli Lilly and Company an emergency use authorization for bamlanivimab to treat mild-to-moderate COVID-19 in adult and pediatric patients.

Healthcare professionals share in the responsibility for minimizing prescription drug abuse and drug diversion. Physicians are tasked with differentiating patients in need of effective pain management from those who may be seeking drugs for inappropriate reasons. Review this Risk Management Tip from MLMIC to reinforce related policies and protocols within your practice or facility.

The U.S. Food and Drug Administration has approved the antiviral drug remdesivir, sold as Veklury, to treat COVID-19 patients who meet specific criteria.